ANI Pharmaceuticals, Inc. (ANIP)
After hours:
| Previous Close | 63.46 |
| Open | 63.62 |
| Bid | 64.69 x 100 |
| Ask | 65.08 x 100 |
| Day's Range | 63.19 - 64.96 |
| 52 Week Range | 47.44 - 70.81 |
| Volume | |
| Avg. Volume | 150,244 |
| Market Cap | 1.36B |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | 40.31 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference
BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows: Date:June 5, 2024 Time:4:30 ET Webcast:Click Here To schedule a 1x1 meeting with the Company, please contact your Jefferies representative. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified bio
- GlobeNewswire
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. "The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited m
- GlobeNewswire
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82Delivered record adjusted non-GAAP EBITDA of $37.6 million, and adjusted non-GAAP diluted earnings per share of $1.21Rare Disease business delivered Q1 net revenues of $36.9 million, representing year-over-year growth of 126.2%Reiterated 2024 guidance of net revenues of $520 million to $542 million,
